 |
 |
We have a new job in the field of genetics , are you working in industry or academia and looking for career progression ?: 1. Work closely with members of Clinical Pharmacogenomics in identifying study objectives and translating them into specific statistical questions. 2. a. These will typically be documented at a high level in the study protocol and in some detail in the joint Pharmacogenomic (PG) and Statistics analysis plan. Consideration should be given to power and sample size, possible confounding variables, multiplicity issues and to the likely presentation of results. b. Careful consideration must be given to the source of data: clinical trials, academic collaborators, de novo prospective studies, family studies, etc. and whether study objectives can be met with the proposed data. Likewise, phenotype definition (clinical endpoint or case-control definition) must also be given careful consideration. c. Generally, this will involve some collaboration with the project statistician assigned to the compound or therapeutic area, to ensure that relevant information is shared in both directions. d. Many studies are of the case-control type and much of the work is exploratory in nature. It is essential to give clear advice about the statistical aspects of such studies, both to the Clinical Pharmacogenomics group and to other statisticians, whose experience typically does not include the design and analysis of case-control studies. 3. Work closely with colleagues in Biostatistics & Reporting and in Clinical Pharmacogenomics to ensure the implementation of the statistical analyses described in the joint PG/B&R pharmacogenomic analysis plan, together with such reasonable data-driven additional analyses as may be agreed upon to facilitate sufficient understanding of the data. a. Explanatory tables, listings and plots may be produced by Statistical Programming support under guidance of the job-holder, or by the job holder. b. Statistical analyses may be conducted by the job-holder or, on occasion, by a project statistician under guidance of the job-holder. c. Whilst the analysis plan will have anticipated the major statistical analyses to be undertaken, the work is typically of an exploratory nature. The job-holder should remain aware of the study objectives and should advise about the suitability and the sufficiency of the analyses undertaken or proposed throughout the reporting phase. d. Ensure that the Clinical Pharmacogenomic study report contains relevant and correct statistical information, contributing relevant sections and reviewing the contribution of other statisticians where necessary. 4. Work closely with Clinical Pharmacogenomics on the design of strategies and programmes of work to ensure that the resultant studies and results will be of a high statistical quality. 5. Identify statistical issues and propose resolutions in areas affecting Clinical Pharmacogenomics. a. Discuss issues with B&R colleagues active in the Clinical Pharmacogenomics area at other sites, in particular, with the statistician associated with the Pharmacogenomics Centre of Emphasis(COE) b. Monitor literature for relevant developments in statistical methods for pharmacogenomics and where appropriate, involve the Statistical Research & Consulting Centre in the development and adoption of new and improved statistical methods. 6. Share experience and knowledge of statistical matters relating to Clinical Pharmacogenomics with other statisticians in B&R, both at Sandwich and at other sites, through internal seminars and project meetings. Natalie Fforde Managing Director Fforde-Management Ltd Curtis House 34 Third Ave Hove BN3 2PD Tel: 01273 722366 Fax: 01273 325350 Mobile: 07769 700 222 www.fforde-management.com